Inflammation in HFpEF: Key or circumstantial?

International Journal of Cardiology

Volumn 189, Issue 1, 2015, Pages 259-263

  Van Empel, Vanessa ^a   Brunner La Rocca, Hans Peter ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Endothelial dysfunction; Heart failure; Heart failure with preserved ejection fraction; Heart failure with reduced ejection fraction; Inflammation; Oxidative stress

Indexed keywords

C REACTIVE PROTEIN; GROWTH DIFFERENTIATION FACTOR 15; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 16; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 18; NITRIC OXIDE; PARICALCITOL; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; BIOLOGICAL MARKER;

ARTICLE; CARDITIS; CLINICAL EFFECTIVENESS; COMORBIDITY; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT PLANNING; ANIMAL; FEMALE; FORWARD HEART FAILURE; HEART FAILURE; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; INFLAMMATION; MALE; METABOLISM; PHYSIOLOGY; PROGNOSIS; VASCULAR ENDOTHELIUM;

ANIMALS; BIOMARKERS; CARDIAC OUTPUT, LOW; ENDOTHELIUM, VASCULAR; FEMALE; HEART FAILURE; HUMANS; INFLAMMATION; MALE; OXIDATIVE STRESS; PROGNOSIS; STROKE VOLUME; VENTRICULAR REMODELING;

EID: 84929325742     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.04.110     Document Type: Review

References (43)

1. W.J. Paulus, C. Tschope, A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation, J. Am. Coll. Cardiol. 62 (2013) 263-271.
2. C.S. Lam, E. Donal, E. Kraigher-Krainer, R.S. Vasan, Epidemiology and clinical course of heart failure with preserved ejection fraction, Eur. J. Heart Fail. 13 (2011) 18-28.
3. K. Sharma, D.A. Kass, Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies, Circ. Res. 115 (2014) 79-96.
4. S.F. Mohammed, B.A. Borlaug, S. McNulty, et al., Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX Trial Ancillary Study, Circ. Heart Fail. 7 (2014) 580-589.
5. C.S. Lam, V.L. Roger, R.J. Rodeheffer, B.A. Borlaug, F.T. Enders, M.M. Redfield, Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study, J. Am. Coll. Cardiol. 53 (2009) 1119-1126.
6. T.E. Owan, D.O. Hodge, R.M. Herges, S.J. Jacobsen, V.L. Roger, M.M. Redfield, Trends in prevalence and outcome of heart failure with preserved ejection fraction, N. Engl. J. Med. 355 (2006) 251-259.
7. S.F. Mohammed, B.A. Borlaug, V.L. Roger, et al., Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study, Circ. Heart Fail. 5 (2012) 710-719.
8. N. Hinglais, D. Heudes, A. Nicoletti, et al., Colocalization of myocardial fibrosis and inflammatory cells in rats, Lab. Investig. J. Tech. Methods Pathol. 70 (1994) 286-294.
9. A. Nicoletti, D. Heudes, N. Hinglais, et al., Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone, Hypertension 26 (1995) 101-111.
10. F. Kuwahara, H. Kai, K. Tokuda, et al., Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 43 (2004) 739-745.
11. S.B. Haudek, J. Cheng, J. Du, et al., Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy, J. Mol. Cell. Cardiol. 49 (2010) 499-507.
12. A.T. Whaley-Connell, J. Habibi, A. Aroor, et al., Salt loading exacerbates diastolic dysfunction and cardiac remodeling in young female Ren2 rats, Metab. Clin. Exp. 62 (2013) 1761-1771.
13. M. Takatsu, C. Nakashima, K. Takahashi, et al., Calorie restriction attenuates cardiac remodeling and diastolic dysfunction in a rat model of metabolic syndrome, Hypertension 62 (2013) 957-965.
14. A. Iyer, T.M. Woodruff, M.C. Wu, et al., Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats, J. Cardiovasc. Pharmacol. 58 (2011) 479-486.
15. E.M. Seymour, R.V. Parikh, A.A. Singer, S.F. Bolling, Moderate calorie restriction improves cardiac remodeling and diastolic dysfunction in the Dahl-SS rat, J. Mol. Cell. Cardiol. 41 (2006) 661-668.
16. R.B. Nunes, J.P. Alves, L.P. Kessler, Lago P. Dal, Aerobic exercise improves the inflammatory profile correlated with cardiac remodeling and function in chronic heart failure rats, Clinics (Sao Paulo) 68 (2013) 876-882.
17. S. Tamaki, T. Mano, Y. Sakata, et al., Interleukin-16 promotes cardiac fibrosis and myocardial stiffening in heart failure with preserved ejection fraction, PLoS One 8 (2013) e68893.
18. Y. Zhang, S. Xing, J. Zhang, et al., Reduction of beta-amyloid deposits by gamma-secretase inhibitor is associated with the attenuation of secondary damage in the ipsilateral thalamus and sensory functional improvement after focal cortical infarction in hypertensive rats, J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 31 (2011) 572-579.
19. W. Liu, X. Wang, W. Feng, et al., Lentivirus mediated IL-17R blockade improves diastolic cardiac function in spontaneously hypertensive rats, Exp. Mol. Pathol. 91 (2011) 362-367.
20. S. Sciarretta, A. Ferrucci, G.M. Ciavarella, et al., Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome, Am. J. Hypertens. 20 (2007) 784-791.
21. E.S. Williams, S.J. Shah, S. Ali, B.Y. Na, N.B. Schiller, M.A. Whooley, C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study, Eur. J. Heart Fail. 10 (2008) 63-69.
22. P. Collier, C.J. Watson, V. Voon, et al., Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur. J. Heart Fail. 13 (2011) 1087-1095.
23. K.B. Shah, W.J. Kop, R.H. Christenson, et al., Prognostic utility of ST2 in patients with acute dyspnea and preserved left-ventricular ejection fraction, Clin. Chem. 57 (2011) 874-882.
24. J. Matsubara, S. Sugiyama, T. Nozaki, et al., Pentraxin 3 is a new inflammatory marker correlated with left-ventricular diastolic dysfunction and heart failure with normal ejection fraction, J. Am. Coll. Cardiol. 57 (2011) 861-869.
25. R.A. de Boer, D.J. Lok, T. Jaarsma, et al., Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction, Ann. Med. 43 (2011) 60-68.
26. C.M. O'Seaghdha, S.J. Hwang, J.E. Ho, R.S. Vasan, D. Levy, C.S. Fox, Elevated galectin-3 precedes the development of CKD, J. Am. Soc. Nephrol. 24 (2013) 1470-1477.
27. O.F. AbouEzzeddine, P. Haines, S. Stevens, et al., Galectin-3 in heart failure with preserved ejection fraction: a RELAX Trial Substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure), JACC Heart Fail. 3 (2015) 245-252.
28. R. Santhanakrishnan, J.P. Chong, T.P. Ng, et al., Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction, Eur. J. Heart Fail. 14 (2012) 1338-1347.
29. A. Kalogeropoulos, V. Georgiopoulou, B.M. Psaty, et al., Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study, J. Am. Coll. Cardiol. 55 (2010) 2129-2137.
30. C.N. Marti, H. Khan, D.L. Mann, et al., Soluble tumor necrosis factor receptors and heart failure risk in older adults: Health, Aging, and Body Composition (Health ABC) Study, Circ. Heart Fail. 7 (2014) 5-11.
31. D. Westermann, D. Lindner, M. Kasner, et al., Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction, Circ. Heart Fail. 4 (2011) 44-52.
32. N. Glezeva, J.A. Baugh, Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target, Heart Fail. Rev. 19 (9) (2014) 681-694.
33. E. Akiyama, S. Sugiyama, Y. Matsuzawa, et al., Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left-ventricular ejection fraction, J. Am. Coll. Cardiol. 60 (2012) 1778-1786.
34. B.A. Borlaug, T.P. Olson, C.S. Lam, et al., Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction, J. Am. Coll. Cardiol. 56 (2010) 845-854.
35. A. Borbely, I. Falcao-Pires, L. van Heerebeek, et al., Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium, Circ. Res. 104 (2009) 780-786.
36. E. Takimoto, H.C. Champion, M. Li, et al., Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy, Nat. Med. 11 (2005) 214-222.
37. M. Guazzi, M. Vicenzi, R. Arena, Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study, Eur. J. Heart Fail. 14 (2012) 82-90.
38. K. Ramasubbu, J. Estep, D.L. White, A. Deswal, D.L. Mann, Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy, J. Am. Coll. Cardiol. 51 (2008) 415-426.
39. H. Fukuta, D.C. Sane, S. Brucks, W.C. Little, Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report, Circulation 112 (2005) 357-363.
40. L. Tavazzi, A.P. Maggioni, R. Marchioli, et al., Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial, Lancet 372 (2008) 1231-1239.
41. B.W. Van Tassell, R. Arena, G. Biondi-Zoccai, et al., Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study), Am. J. Cardiol. 113 (2014) 321-327.
42. M.M. Redfield, H.H. Chen, B.A. Borlaug, et al., Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial, JAMA J. Am. Med. Assoc. 309 (2013) 1268-1277.
43. P.M. Ridker, E. Danielson, F.A. Fonseca, et al., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, The New England J. Med. 359 (2008) 2195-2207.